In Vitro Evaluation of Olorofim and Amphotericin B Combination Therapy Against Talaromyces marneffei
Journal of Fungi · 17.06.2026 · 12 (6) · 441
DOI: 10.3390/jof12060441 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Fungi, online erschienen am 17.06.2026. Verfasst von Le Hoang Ngoc Lan und 9 weiteren Autor:innen. Beteiligte Einrichtung: International University, Ho Chi Minh City 700000, Vietnam. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Institutes of Health, Pham Ngoc Thach University of Medicine in Ho Chi Minh City, Vietnam.
Abstract (Originalsprache)
The dimorphic fungus Talaromyces marneffei causes talaromycosis, a life-threatening fungal disease with limited treatment options. Olorofim, a first-in-class orotomide antifungal that targets pyrimidine synthesis essential for fungal growth, has low minimum inhibitory concentration (MIC) against T. marneffei and clinical efficacy against other invasive fungal diseases. Here, we tested the hypothesis that olorofim synergistically enhances amphotericin B (AmB), a potent membrane-targeting antifungal, against T. marneffei in 55 clinical isolates using a validated colorimetric checkerboard assay. The MIC was defined as the lowest drug concentration inhibiting ≥ 95% of fungal growth. Drug interactions were assessed using the fractional inhibitory concentration index (FICI), which defines ≤0.5 as synergy, 0.5 < FICI ≤ 4.0 as indifference, and FICI > 4 as antagonism. We found that interactions between AmB and olorofim were indifferent across all 55 isolates (0.5 < FICI ≤ 1.03). Time-kill assays showed an expected concentration-dependent fungicidal activity for AmB, but a concentration-independent fungistatic activity for olorofim against T. marneffei. Combinations of AmB and olorofim were also indifferent in time-kill experiments. Although synergy was not observed, and olorofim is unlikely to enhance AmB induction therapy, olorofim may have a role in the consolidation and maintenance therapy of talaromycosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- International University, Ho Chi Minh City 700000, Vietnam.
- Vietnam National University, Ho Chi Minh City 720325, Vietnam.
- Tropical Medicine Research Center for Talaromycosis, Biomedical Research and Diagnostics Center, Pham Ngoc Thach University of Medicine, Ho Chi Minh City 700000, Vietnam.
- Division of Infectious Diseases and International Health, Duke University School of Medicine, Durham, NC 27710, USA.
- Department of Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool L69 7ZB, UK.
- The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
ORCID-Profile: Heera Natesan Sambath, Lottie Brown, Shawin Vitsupakorn, Nguyen Thi Thu Hoai
Förderung
- NIH HHS
- National Institutes of Health
- Pham Ngoc Thach University of Medicine in Ho Chi Minh City, Vietnam
Zitieren
APA
Lan, L. H. N., Natesan Sambath, H., Brown, L., Thu, N. T. M., Vitsupakorn, S., My, P. T. H., Khanh, D. H., Hoai, N. T. T., Hoa, N. T., & Le, T. (2026). In Vitro Evaluation of Olorofim and Amphotericin B Combination Therapy Against Talaromyces marneffei. Journal of Fungi, 12(6), 441. https://doi.org/10.3390/jof12060441
Vancouver
Lan LHN, Natesan Sambath H, Brown L, Thu NTM, Vitsupakorn S, My PTH, et al. In Vitro Evaluation of Olorofim and Amphotericin B Combination Therapy Against Talaromyces marneffei. Journal of Fungi. 2026;12(6):441. doi:10.3390/jof12060441
BibTeX
@article{Lan2026,
author = {Lan, Le Hoang Ngoc and Natesan Sambath, Heera and Brown, Lottie and Thu, Nguyen Thi Mai and Vitsupakorn, Shawin and My, Phan Thi Ha and Khanh, Dang Hoang and Hoai, Nguyen Thi Thu and Hoa, Ngo Thi and Le, Thuy},
title = {In Vitro Evaluation of Olorofim and Amphotericin B Combination Therapy Against Talaromyces marneffei},
journal = {Journal of Fungi},
year = {2026},
volume = {12},
number = {6},
pages = {441},
doi = {10.3390/jof12060441}
}
EUVIMED